Intellia Therapeutics (NTLA) Net Equity Issued and Repurchased (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Net Equity Issued and Repurchased for 9 consecutive years, with $750.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $750.0 million; the TTM figure through Mar 2026 stood at $878.2 million (up 638.8% YoY), while the FY2025 annual figure was $128.2 million, down 27.54% from the prior year.
• Net Equity Issued and Repurchased climbed to $750.0 million in Q1 2026 per NTLA's latest filing, from $114.5 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $750.0 million in Q1 2026 and bottomed at -$361.1 million in Q2 2022.
• Historically, Net Equity Issued and Repurchased has averaged $112.5 million across 5 years, with a median of $47.2 million in 2024.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased slumped 99.63% — and 2024, when it soared 3858.66%.
• Intellia Therapeutics' Net Equity Issued and Repurchased stood at $337.9 million in 2022, then slumped by 69.33% to $103.6 million in 2023, then tumbled by 98.07% to $2.0 million in 2024, then surged by 5626.61% to $114.5 million in 2025, then soared by 555.16% to $750.0 million in 2026.
• Business Quant data shows NTLA's Net Equity Issued and Repurchased at $750.0 million in Q1 2026, $114.5 million in Q3 2025, and $13.7 million in Q2 2025.